Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMY)
Filing Type: Form 8-K (Current Report)
Date of Report: February 2, 2024
Reporting Period: Fourth Quarter and Full Year 2023
This filing serves as a notification that the Company issued an Earnings Press Release and a presentation regarding its financial results for the fourth quarter and full year of 2023. The detailed financial data is contained in the attached exhibits (Exhibit 99.1 and 99.2) and is incorporated by reference.
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are disclosed in the Earnings Press Release (Exhibit 99.1) and the Bristol Myers Presentation (Exhibit 99.2), which are referenced but not included in the body of this 8-K summary.
Material Changes
Comparison to Prior Period: The filing text does not provide specific data on material changes versus the prior comparable period. The Company directs investors to the Earnings Press Release for details on year-over-year performance and non-GAAP reconciliations.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The Company posted a presentation on its website detailing financial and operating initiatives. This presentation includes references to non-GAAP financial information and should be read in conjunction with the Earnings Press Release.
Regulatory Note: Pursuant to General Instruction B.2, the information in Item 7.01 (including the presentation) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities thereof, nor is it incorporated by reference into future filings unless specifically provided.
Investor Verification Checklist
- Review Exhibit 99.1 (Earnings Press Release) for specific Q4 and Full Year 2023 revenue, net income, and EPS figures.
- Examine Exhibit 99.2 (Presentation Materials) for management's outlook, operating initiatives, and non-GAAP reconciliations.
- Verify the availability of the presentation on the Company's website (www.bms.com), noting the Company reserves the right to discontinue access at any time.
- Confirm the trading symbols for the Company's securities: Common Stock (BMY), 1.000% Notes due 2025 (BMY25), 1.750% Notes due 2035 (BMY35), and Celgene Contingent Value Rights (CELG RT).